Physician profile
Karen Newsome
NPI 1316547714
$13,215.48
in general payments reported to CMS, 2019-2025
38 companies · $3,716 in 2025
The $3,716 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $2,018 · 2023: $3,404 · 2024: $3,657 · 2025: $3,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,446.33 |
| Education | $331.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,575.29 | 2021-2025 | |
| Amgen INC. | $1,606.66 | 2022-2025 | Enbrel, Krystexxa, Otezla |
| Janssen Biotech, INC. | $1,463.40 | 2022-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $1,249.03 | 2022-2025 | Acthar |
| Ucb, INC. | $938.37 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $808.72 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $644.47 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $386.42 | 2022-2025 | Taltz, Zepbound |
| Genzyme Corporation | $342.42 | 2023-2025 | |
| Glaxosmithkline, LLC. | $310.38 | 2022-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $271.01 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $265.70 | 2024-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.43 | 2022-2025 | Ofev, Cyltezo, Spevigo |
| Sobi, INC | $211.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $210.89 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $193.38 | 2022-2024 | Tymlos |
| Si-Bone, INC. | $175.02 | 2024-2025 | |
| Depuy Synthes Sales INC. | $173.68 | 2022-2025 | Monovisc, Orthovisc |
| Organon LLC | $140.14 | 2022-2025 | Hadlima, Renflexis |
| Almatica Pharma LLC | $101.36 | 2022-2025 | Teriparatide, Gralise |
| Therapeuticsmd, INC. | $99.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $95.21 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $73.78 | 2025 | Strensiq |
| Azurity Pharmaceuticals, INC. | $70.44 | 2023-2025 | Horizant, Horizant |
| Fresenius Kabi USA, LLC | $67.53 | 2024-2025 | Idacio |
| Sandoz INC. | $65.40 | 2024-2025 | Hyrimoz, Jubbonti |
| Actelion Pharmaceuticals US, INC. | $64.57 | 2024 | Opsumit, Uptravi |
| Agile Therapeutics, INC. | $58.73 | 2021 | |
| Pfizer INC. | $58.03 | 2021-2024 | |
| Grifols USA, LLC | $56.62 | 2024-2025 | Gamunex-C |
| Myovant Sciences INC. | $55.87 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $40.76 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.80 | 2021 | |
| Mayne Pharma Commercial LLC | $26.17 | 2021 | |
| Tonix Medicines, INC. | $24.07 | 2025 | Tonmya |
| Biogen, INC. | $20.42 | 2023 | Tysabri |
| Genentech USA, INC. | $19.36 | 2025 | Gazyva |
| Coopersurgical, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Newsome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.